Comparative Pharmacology
Head-to-head clinical analysis: ELAHERE versus PURINETHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAHERE versus PURINETHOL.
ELAHERE vs PURINETHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). It consists of a humanized anti-FRα antibody conjugated to the maytansinoid DM4, a microtubule inhibitor. Upon binding to FRα on tumor cells, the ADC is internalized and releases DM4, which binds to tubulin and disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis.
Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.
6 mg/kg adjusted ideal body weight intravenously every 3 weeks until disease progression or unacceptable toxicity.
1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.
None Documented
None Documented
Terminal half-life approximately 6.2 days (range 3.7-9.5 days) after IV administration; supports every-3-week dosing interval.
The terminal elimination half-life of mercaptopurine is approximately 1.5 hours. However, the active metabolite 6-thioguanine nucleotides have a half-life of 5-7 days, correlating with pharmacological effects.
Fecal (approximately 80%) as unchanged drug; renal (approximately 8%) as unchanged drug and metabolites.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 50% of elimination. Biliary excretion contributes to a minor extent (<10%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent